摘要
目的观察吗替麦考酚酯(MMF)分散片联合泼尼松治疗难治性肾病综合征(RNS)的疗效性及安全性。方法采用前瞻性多中心对照方法,10个中心共142例患者入选。治疗组87例,对照组55例。治疗组以MMF分散片(每日30～40mg/kg)联合泼尼松(每日0.5～1mg/kg)治疗,服MMF6个月后,如无效应者停药,有效者减量维持治疗6个月,维持剂量每日10～20mg/kg;对照组以环磷酰胺(CTX)冲击,每2周连用2d,每日10mg/kg联合泼尼松治疗,疗程3个月,随后第4,7,10个月的第1天分别给予CTX500mg/m2,静脉点滴1次。泼尼松服用2～3个月开始减量。定期检测尿蛋白、肝肾功能及药物副作用。观察随访期共1年。结果MMF治疗组87例中58例获完全效应,16例部分效应,9例表现为早期效应,4例治疗失败,治疗总有效率95.4%,尿蛋白转阴67例(77%);CTX组55例中35例获完全效应,9例部分效应,1例早期效应,10例治疗失败,治疗总有效率81.8%,尿蛋白转阴36例(65.4%)。两组尿蛋白转阴率统计学差异无显著性,有效率MMF治疗组较CTX组高,而且有统计学意义(P<0.01)。尿蛋白转阴天数、低蛋白血症恢复天数、尿量恢复时间、高脂血症、水肿消退时间等方面MMF明显优于CTX。MMF治疗组用药期间主要副作用有一过性转氨酶升高3例次、感染32例次、消化道症状11例次、月经紊乱、肌肉颤动各1例次;对照组发生转氨酶升高9例次、感染30例次、消化道症状15例次、血红蛋白降低4例次、白细胞降低2例次、脱发7例次。结论结果表明,推荐MMF每日20～35mg/kg联合泼尼松0.5～1mg/kg治疗难治性肾病综合征,尿蛋白转阴率不劣于CTX,而且起效时间较CTX短,药物副作用少。
Objective To evaluate the efficacy and safety of mycophenolate mofetil （MMF） plus prednisone on refractory nephrotic syndrome （RNS） in children. Methods One hundred and forty-two children with RNS from ten clinical trial centers were divided into two groups： MMF （n = 87） and control （n = 55）. The MMF group patients were administered with oral MMF （30-40 mg/kg daily） for at least 6 months. Afterwards the patients who responded to MMF received another 6 months MMF treatment at a dosage of 10-20 mg/kg daily. The controls were treated with pulse intravenous infusion of cyclophosphamide （CTX） （ 10 mg/kg daily） for 2 days every 2 weeks for 3 months. Then CTX was administered at a dosage of 500 mg/m^2 once a month 4, 7 and 10 months after treatment. While the patients received MMF or CTX treatment, they were treated with oral prednisone （0.5-1 mg/kg daily） for 2 to 3 months, and then the dosage of prednisone was gradually reduced. Urinary protein, liver and renal functions, and side effects of drugs were examined at regular intervals for one year. Results Of the 87 patients, 58 achieved complete remission, 16 achieved partial remission, 9 achieved early remission and 4 had no response to treatment. In the control group, 35 achieved complete remission, 9 achieved partial remission, 1 achieved early remission and 10 had no response to treatment. The total remission rate in the MMF group （95.4%） was significantly higher than that in the control group （81.8%） （P 〈 0. 01 ）. After treatment 67 patients （65.4%） in the MMF group had negative proteinuria compared with 36 patients （65.4%） in the control group （P 〉 0. 05 ）. MMF was found to be more effective in reducing proteinuria, and improving hypoproteinemia, oliguria, hyperlipemia, and edema than CTX. MMF was better tolerated with lower incidences of adverse reactions than CTX. Conclusions The combined therapy of MMF and prednisone is more effective and tolerable than pulse intravenous infusion of CTX for treatment of RNS in children.
出处
《中国当代儿科杂志》
CAS
CSCD
2008年第5期575-578,共4页
Chinese Journal of Contemporary Pediatrics
关键词
吗替麦考酚酯
肾病综合征
多中心临床试验
儿童
Mycophenolate mofetil
Nephrotic syndrome
Muhicenter. clinical trial
Child
